PET/CT in the management of thyroid cancers

Charles Marcus, Pat W. Whitworth, Devaki S. Surasi, Sara I. Pai, Rathan M. Subramaniam

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

OBJECTIVE. Thyroid cancer is the most common endocrine cancer. This review evaluates the established use of 18F-FDG PET/CT in papillary, follicular, Hürthle cell, anaplastic, and medullary thyroid cancers. The significance of incidental diffuse and focal thyroid FDG uptake is discussed. The evolving value of non-FDG radiotracers, including 124I, 18F-dihydroxyphenylalanine, and 68Ga somatostatin analogs, is summarized. CONCLUSION. PET/CT is a valuable imaging test, in the appropriate clinical context, for the management of thyroid cancers.

Original languageEnglish (US)
Pages (from-to)1316-1329
Number of pages14
JournalAmerican Journal of Roentgenology
Volume202
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • F-DOPA PET/CT
  • FDG PET/CT
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'PET/CT in the management of thyroid cancers'. Together they form a unique fingerprint.

  • Cite this

    Marcus, C., Whitworth, P. W., Surasi, D. S., Pai, S. I., & Subramaniam, R. M. (2014). PET/CT in the management of thyroid cancers. American Journal of Roentgenology, 202(6), 1316-1329. https://doi.org/10.2214/AJR.13.11673